Influence of anti-TNF therapy on bone metabolism in patients with inflammatory bowel disease

Eur J Intern Med. 2017 Apr:39:e33-e34. doi: 10.1016/j.ejim.2017.01.024. Epub 2017 Feb 3.

Authors

Beatriz Castro¹, Montserrat Rivero¹, Javier Crespo¹, J Antonio Riancho², Carmen Valero³

Affiliations

¹ Gastroenterology and Hepatology Unit, University Hospital Marqués de Valdecilla, University of Cantabria, IDIVAL, Santander, Spain.
² Department of Internal Medicine, University Hospital Marqués de Valdecilla, University of Cantabria, IDIVAL, Santander, Spain.
³ Department of Internal Medicine, University Hospital Marqués de Valdecilla, University of Cantabria, IDIVAL, Santander, Spain. Electronic address: mirvdc@humv.es.

PMID: 28169065
DOI: 10.1016/j.ejim.2017.01.024

No abstract available

Publication types

Letter

MeSH terms

Adalimumab / therapeutic use*
Adult
Aged
Bone Density / drug effects*
Calcifediol / blood
Female
Hospitals, University
Humans
Inflammatory Bowel Diseases / drug therapy*
Infliximab / therapeutic use*
Male
Middle Aged
Osteoporosis / epidemiology
Spain
Tumor Necrosis Factor-alpha / antagonists & inhibitors*
Young Adult

Substances

Tumor Necrosis Factor-alpha
Infliximab
Adalimumab
Calcifediol